Ally Bridge Group »

Inhibikase Therapeutics shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.2M 1.3M 1.68

More positions owned by Ally Bridge Group

Soleno Therapeutics (SLNO)
Praxis Precision Medicines I Com New (PRAX)
Minerva Neurosciences Com New (NERV)
Ovid Therapeutics (OVID)
Compass Pathways Sponsored Ads (CMPS)
Tarsus Pharmaceuticals (TARS)
Solid Biosciences Com New (SLDB)
Compass Therapeutics Call Option (CMPX)
Promis Neurosciences Com Shs (PMN)
Edgewise Therapeutics (EWTX)
Uniqure Nv SHS Call Option (QURE)
Eupraxia Pharmaceuticals (EPRX)
Cytomx Therapeutics (CTMX)
Inventiva Sa Ads (IVA)
Perspective Therapeutics Com New (CATX)

View all positions for Ally Bridge Group

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Trails Edge Capital Partners
ADAR1 Capital Management
BlackRock
Blackstone Group
Siren
Commodore Capital
Vanguard Group
Vanguard Capital Management
Saturn V Capital Management
Kalehua Capital Management
Squadron Capital Management
Millennium Management

View all funds holding Inhibikase Therapeutics